Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$89.51 USD

89.51
6,484,782

+0.69 (0.78%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $89.55 +0.04 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (GILD) Outperforming Other Medical Stocks This Year?

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

Zachary Stutler headshot

5 Biotech Stocks to Buy Right Now

by Zachary Stutler

here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.

Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO

by Zacks Equity Research

Gilead (GILD) presents data from a phase I study on experimental CAR T cell therapy, KTE-X19, at ASCO and announces collaboration with Humanigen.

Why Is Gilead (GILD) Down 3% Since Last Earnings Report?

by Zacks Equity Research

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $63.34, moving -0.05% from the previous trading session.

GILD or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GILD vs. ILMN: Which Stock Is the Better Value Option?

Gilead Gains 6.8% YTD as HIV Franchise Maintains Momentum

by Zacks Equity Research

Gilead (GILD) up 6.9% in the year so far on strong performance of HIV franchise and pipeline development efforts.

Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason

by Zacks Equity Research

Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (GILD) Outperforming Other Medical Stocks This Year?

Agenus' (AGEN) Pipeline Progression on Track Amid Competition

by Zacks Equity Research

Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.

Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary

by Zacks Equity Research

Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.

Urmimala Biswas headshot

5 Best PEG Stocks Suitable for GARP Investors

by Urmimala Biswas

While P/E alone only gives an idea of stocks that are trading at a discount, PEG, while adding the growth element to it, helps to identify stocks that have solid potential.

Lilly's Crohn's Disease Candidate Meets Phase II Study Goals

by Zacks Equity Research

Lilly's (LLY) mirikizumab met primary endpoint and key secondary endpoints in phase II Crohn's disease study.

The Zacks Analyst Blog Highlights: Disney, Coca-Cola, Gilead, CME and Entergy

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Disney, Coca-Cola, Gilead, CME and Entergy

Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?

by Zacks Equity Research

Alexion (ALXN) gains 30.7% on solid performance of lead drug Soliris and approval of Ultomiris.

Mark Vickery headshot

Top Stock Reports for Disney, Coca-Cola & Gilead

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Coca-Cola (KO) and Gilead (GILD).

Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study

by Zacks Equity Research

Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.

Mallinckrodt Ends Enrollment in Phase III for Terlipressin

by Zacks Equity Research

Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.

Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates

by Zacks Equity Research

Key highlights of the past week are regulatory and pipeline updates by the leading biotech companies.

John Blank headshot

What's Next for Trade-War Tactics? Global Week Ahead

by John Blank

In this Global Week Ahead, the week???s macro calendar shrinks back, when compared to weighing trade war tactics. Wednesday's dump of Mainland China macro data and U.S. retail sales is the bona fide exception.

GILD vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

GILD vs. ILMN: Which Stock Is the Better Value Option?

Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1

by Zacks Equity Research

Global Blood (GBT) reports narrower-than-expected loss in the first quarter of 2019.

Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.

PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y

by Zacks Equity Research

PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues